Comparative efficacy of tapinarof regimens in atopic dermatitis

Summaries 1 min 15

Font Size

Created On: 30/10/2026

Atopic dermatitis (AD) is a complex, chronic inflammatory skin disorder marked by severe pruritus and recurrent eczematous lesions that substantially hamper overall patient quality of life.

See All

Key take away

Tapinarof 1% cream applied twice daily achieves the highest therapeutic efficacy for atopic dermatitis, significantly improving EASI and IGA scores with a favorable safety profile.

Background

Atopic dermatitis (AD) is a complex, chronic inflammatory skin disorder marked by severe pruritus and recurrent eczematous lesions that substantially hamper overall patient quality of life. Tapinarof, a novel nonsteroidal aryl hydrocarbon receptor (AhR) modulator, has emerged as a promising topical therapeutic agent. However, determining the optimal drug concentration and dosing frequency needed to balance therapeutic benefits against adverse effects has remained vague.

Method

A comprehensive search of Web of Science, ProQuest, Scopus, MEDLINE/PubMed, and the Cochrane Central Register of Controlled Trials (CENTRAL) was carried out. Five randomized controlled trials (RCTs) involving 1,506 subjects were included in a frequentist network meta-analysis comparing tapinarof cream at concentrations of 0.5%, 1%, and 2%, given once or twice daily, against placebo.

Effectiveness was assessed using at least 75% betterment in the Eczema Area and Severity Index (EASI-75) and Investigator’s Global Assessment (IGA) response. Treatment rankings were determined via surface under the cumulative ranking curve (SUCRA) probabilities.

Result

Among the evaluated regimens, tapinarof 1% cream twice daily attained the highest efficacy ranking, with an odds ratio (OR) of 1.89 for EASI-75 and an OR of 2.40 for IGA response. Its SUCRA score was 70.3%. Among the evaluated regimens, tapinarof 1% once daily and 0.5% twice daily showed moderate effects, while tapinarof 0.5% once daily and placebo performed least favourably. Heterogeneity was minimal for EASI-75 (I²=1.4%) but moderate for IGA response (I²=67.14%). The safety profile was generally favorable, with adverse events typically mild. Folliculitis and contact dermatitis were among the most frequently reported events.

Conclusion

Tapinarof 1% cream given twice daily depicted the most potent and well-tolerated dosing strategy among evaluated topical regimens for tackling AD. While these findings yield critical, evidence-based guidance for dermatologic practice and clinical decision-making, direct head-to-head trials remain necessary to confirm comparative superiority across varying concentrations and dosing intervals.